China Pharma Cash Flow - Annual (NYSEMKT:CPHI)

Add to My Stocks
$0.25 $0 (0%) CPHI stock closing price Jun 15, 2018 (Closing)

The China Pharma cash flow statement helps investors understand how well the company is managing its cash flows. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For China Pharma profits one has to check the income statement and for China Pharma debt one has to check the balance sheet. This statement can tell if a company is running out of money while still being profitable and is useful in China Pharma stock analysis. China Pharma had a negative net income cash flow of $-19.27M for the latest 2017. This report is very useful in measuring the short term viability of a company. China Pharma has a negative cash and cash equivalents change of $-0.63M.

View details of China Pharma cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
-19.27M-9.18M-15.4M-26.04M-20M4.61M19.26M23.41M20.23M17.83M
Depreciation Depletion Amortization Cash-Flow3.29M3.07M3.59M1.78M1.61M1.46M1.17M1.5M1.36M-
Net Increase (Decrease) in Assets Liabilities1M3.64M2.9M9.16M9.05M-5.38M-14.61M-16.27M-9.3M-11.87M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net15.81M5.35M12.25M19.66M17.93M2.94M-0.59M-0.86M-1.63M-0.13M
Net Cash from (used by) Operating Activities
-2.89M3.35M4.57M8.59M3.64M5.23M7.78M10.66M6.54M
Increase (Decrease) in Prop Plant And Equipment-0.13M-0.19M-2.31M-5.12M-18.79M-1.76M-0.35M-0.06M-0.14M-4.31M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-------0.08M---
Other Cash Inflow (Outflow) from Investment Activities----0.71M-0.29M-3.21M-5.19M-10.45M-15.21M-6.13M
Net Cash from (used by) Investment Activities
-0.13M-0.19M-1.89M-5.84M-19.09M-4.98M-5.62M-10.51M-15.36M-10.44M
Issuance (Purchase) of Equity Shares-------2.58M-9.26M
Issuance (Repayment) of Debt Securities-1.47M-1.5M--12.32M-----
Increase (Decrease) in Bank & Other Borrowings--4.51M------0.14M1.31M-0.38M
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
-1.47M-6.02M--12.32M1.28M-2.66M1.38M8.88M
Effect of Exchange Rate Changes on Cash--0.26M-0.5M-0.03M------
Net Change in Cash & Cash Equivalents
-0.63M-3.58M--0.69M1.96M-0.02M---3.29M5.09M
Cash & Equivalents at Beginning of Year2.66M6.24M5.29M5.99M4.02M4.05M3.69M3.63M6.92M1.83M
Cash & Equivalents at Year End2.03M2.66M6.24M5.29M5.99M4.02M4.05M3.69M3.63M6.92M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Mylan financial analysis

China Pharma stock price history provides insight into historical stock price fluctuations, and China Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • China Pharma has cash of $2.03M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the China Pharma stock price.
  • The cash generated from the core business or operations was a negative at $- for China Pharma in the latest 2017. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-0.13M for CPHI stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-1.47M for China Pharma.

Key Financial Ratios For China Pharma Cash Flow

FCF margin
0.14